IN THE CLAIMS

Prior to charging any claims fees, please cancel claims 1 - 22 without prejudice or disclaimer. Please add claims 23 – 48 as shown below. This listing of claims will replace all prior versions, and listings, of claims in the application.

Complete Listing of Claims:

Claims 1-22. (Cancelled).

Claim 23. (New) A pharmaceutical composition in the form of a suspension, wherein:

(a) the suspension is produced by constituting a storage stable powder with a liquid medium;

(b) the powder comprises a therapeutically effective amount of at least one acid labile substituted benzimidazole H^+,K^+-ATPase proton pump inhibitor and at least one buffering agent;

(c) the at least one buffering agent is present in the powder in a total amount of about 0.1 mEq to about 2.5 mEq per mg of proton pump inhibitor; and

(d) after constitution, the suspension is substantially stable upon storage in a closed container maintained at 4 °C for a period of at least about 1 day.

Claim 24. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 4 °C for a period of at least about 2 days.

Claim 25. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 4 °C for a period of at least about 7 days.

Claim 26. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 4 °C for a period of at least about 14 days.

Claim 27. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 4 °C for a period of at least about 12 months.

Claim 28. (New) The composition of claim 23, wherein after constitution and storage of the suspension in a closed container maintained at 4 °C for a period of at least about 12 months, at least about 90%, by weight, of said proton pump inhibitor is still present in the suspension.

Claim 29. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 25 °C for a period of at least about 1 day.

Claim 30. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 25 °C for a period of at least about 2 days.

Claim 31. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 25 °C for a period of at least about 7 days.

Claim 32. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 25 °C for a period of at least about 14 days.

Claim 33. (New) The composition of claim 23, wherein after constitution, the suspension is substantially stable upon storage in a closed container maintained at 25 °C for a period of at least about 12 months.

Claim 34. (New) The composition of claim 23, wherein after constitution and storage of the suspension in a closed container maintained at 25 °C for a period of at least about 12 months, at least about 90%, by weight, of said proton pump inhibitor is still present in the suspension.

Claim 35. (New) The composition of claim 23, wherein the at least one proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole (s-omeprazole), pantoprazole, pariprazole, leminoprazole, or an enantiomer, an alkaline salt of an enantiomer, an isomer, a prodrug, a derivative or a salt thereof.

Claim 36. (New) The composition of claim 23, wherein the at least one proton pump inhibitor is omeprazole, or an enantiomer, an alkaline salt of an enantiomer, an isomer, a prodrug, a derivative or a salt thereof.

Claim 37. (New) The composition of claim 23, wherein the at least one proton pump inhibitor is lansoprazole, or an enantiomer, an alkaline salt of an enantiomer, an isomer, a prodrug, a derivative or a salt thereof.

Claim 38. (New) The composition of claim 23, wherein the at least one proton pump inhibitor is esomeprozole, or an enantiomer, an alkaline salt of an enantiomer, an isomer, a prodrug, a derivative or a salt thereof.

Claim 39. (New) The composition of claim 23, wherein the at least one buffering agent is selected from the group consisting of a calcium buffering agent, a magnesium buffering agent, an aluminum buffering agent, a sodium buffering agent, a bicarbonate salt of a Group IA metal, an alkaline earth metal buffering agent, an amino acid, an alkali salt of an amino acid, or mixtures thereof.

Claim 40. (New) The composition of claim 23, wherein the at least one buffering agent is selected from the group consisting of, sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium aluminate, magnesium carbonate, magnesium silicate, magnesium citrate, aluminum hydroxide, aluminum hydroxide/magnesium carbonate, aluminum hydroxide/sodium bicarbonate coprecipitate, aluminum glycinate, sodium citrate, calcium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, potassium carbonate, potassium metaphosphate, calcium acetate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium carbonate, calcium gluconate, calcium bicarbonate, potassium phosphate, potassium citrate, and mixtures thereof.

Claim 41. (New) The composition of claim 23, wherein the at least one buffering agent and the at least one proton pump inhibitor are present in a mEq:mg ratio of about 1:1 to about 1:3.5.

Claim 42. (New) The composition of claim 23, further comprising a pharmaceutically acceptable excipient selected from the group consisting of a binder, a flavoring agent, a sweetening agent, a disintegrant, a flow aid, a lubricant, an adjuvant, an antioxidant, a chelating

agent, an isotonic agent, a thickening agent, a carrier, a colorant, a diluent, a moistening agent, a preservative, a parietal cell activator, and an anti-foaming agent, or combinations thereof.

Claim 43. (New) The composition of claim 23, wherein after constitution, the suspension comprises substantially no solid enteric-coating material.

Claim 44. (New) A method for treating a gastric acid related disorder in a subject in need thereof, the method comprising administering the suspension of claim 23 to the subject.

Claim 45. (New) The method of claim 44, wherein the proton pump inhibitor is omeprazole.

Claim 46. (New) The method of claim 44, wherein the proton pump inhibitor is lansoprazole.

Claim 47. (New) The method of claim 44, wherein the proton pump inhibitor is esomeprazole (s-omeprazole).

Claim 48. (New) The method of claim 44, wherein the gastric acid related disorder is selected from the group consisting of a duodenal ulcer disease, a gastric ulcer disease, a gastroesophageal reflux disease, a erosive esophagitis, a poorly responsive symptomatic gastroesophageal reflux disease, a pathological gastrointestinal hypersecretory disease, and Zollinger Ellison Syndrome.